Antonio Fontanellas

Pamplona, NC 31008, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

New cases of δ-aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model.

New cases of δ-aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model.

Journal: Journal of internal medicine

Published: November 21, 2025

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Journal: Journal of physiology and biochemistry

Published: May 22, 2025

RNA-based therapies in liver metabolic diseases.

RNA-based therapies in liver metabolic diseases.

Journal: Gut

Published: November 11, 2024

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.

Journal: Journal of translational medicine

Published: September 14, 2024

Porphyrins and the porphyrias.

Porphyrins and the porphyrias.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 22, 2024

Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).

Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Clinical science (London, England : 1979)

Published: June 17, 2024

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Journal: Gut

Published: April 09, 2024

Exploring current and emerging therapies for porphyrias.

Exploring current and emerging therapies for porphyrias.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 29, 2024

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.

Journal: International journal of molecular sciences

Published: June 29, 2023

The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders.

The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders.

Journal: Cellular and molecular gastroenterology and hepatology

Published: June 19, 2023

Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.

Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.

Journal: International journal of molecular sciences

Published: November 15, 2022

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment.

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment.

Journal: Life (Basel, Switzerland)

Published: October 20, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026